Barclays analyst Gena Wang lowered the firm’s price target on Bluebird Bio (BLUE) to $2 from $4 and keeps an Overweight rating on the shares. The company reported a Q3 revenue miss due to the timing of infusions, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLUE:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue